Can roflumilast, a phosphodiesterase-4 inhibitor, improve clinical outcomes in patients with moderate-to-severe chronic obstructive pulmonary disease? A meta-analysis

Respiratory Research
Jian LuoChun-Tao Liu

Abstract

Effects of roflumilast on lung function, symptoms, acute exacerbation and adverse events in patients with chronic obstructive pulmonary disease (COPD) are controversial. We aimed to further clarify the efficacy and safety of roflumilast in treatment of moderate-to-severe COPD. From 1946 to November 2015, we searched the Pubmed, Embase, Medline, Cochrane Central Register of Controlled Trials, ISI Web of Science and American College of Physician using "roflumilast" and "chronic obstructive pulmonary disease" or "COPD". Randomized controlled trials that reported forced expiratory volume in one second (FEV1), forced vital capacity (FVC), transition dyspnea index (TDI), St George's Respiratory Questionnaire (SGRQ), and incidence of COPD exacerbations and adverse events were eligible. We conducted the heterogeneities test and sensitivity analysis, and random-effects or fixed-effects model was applied to calculate risk ratio (RR) and mean difference (MD) for dichotomous and continuous data respectively. Cochrane systematic review software, Review Manager (RevMan), was used to test the hypothesis by Mann-Whitney U-test. Thirteen trials with a total of 14,563 patients were pooled in our final studies. Except for SGRQ (I (2) = 63 %, χ (2...Continue Reading

References

Feb 26, 1998·American Journal of Respiratory and Critical Care Medicine·T J Torphy
Feb 5, 2005·Respirology : Official Journal of the Asian Pacific Society of Respirology·UNKNOWN Asia Pacific COPD Roundtable Group
Nov 30, 2006·PLoS Medicine·Colin D Mathers, Dejan Loncar
Dec 2, 2006·COPD·Donald A Mahler, Theodore J Witek
Apr 28, 2007·American Journal of Respiratory and Critical Care Medicine·Peter M A CalverleyLeonardo M Fabbri
Feb 8, 2008·The European Respiratory Journal·D P TashkinS Kesten
Sep 1, 2009·Lancet·Peter M A CalverleyUNKNOWN M2-124 and M2-125 study groups
May 14, 2010·American Journal of Respiratory and Critical Care Medicine·James F DonohueUNKNOWN INHANCE Study Investigators
Sep 17, 2010·The New England Journal of Medicine·John R HurstUNKNOWN Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators
Aug 19, 2011·Respirology : Official Journal of the Asian Pacific Society of Respirology·Sang-Do LeeHan-Pin Kuo
Oct 4, 2011·The European Respiratory Journal·Denis E O'DonnellKatherine A Webb
Mar 24, 2012·The European Respiratory Journal·Paul W JonesEsther Garcia Gil

❮ Previous
Next ❯

Citations

May 14, 2016·Expert Opinion on Drug Discovery·Mario CazzolaMaria Gabriella Matera
Jun 10, 2016·Expert Opinion on Drug Safety·Paola RoglianiMaria Gabriella Matera
Mar 5, 2018·Respirology : Official Journal of the Asian Pacific Society of Respirology·Jian LuoChun-Tao Liu
Mar 24, 2018·Basic & Clinical Pharmacology & Toxicology·Øyvind Nicolay Ulland SalvesenDaniel Pilsgaard Henriksen
Oct 31, 2017·Expert Review of Respiratory Medicine·Mario CazzolaMaria Gabriella Matera
Jun 22, 2017·Respiratory Research·Marc MiravitllesJosé R Jardim
Sep 19, 2017·The Cochrane Database of Systematic Reviews·Jimmy ChongPhillippa Poole
May 2, 2020·The Cochrane Database of Systematic Reviews·Sadia JanjuaPhillippa Poole
Sep 5, 2017·Expert Opinion on Emerging Drugs·Thomas J Monaco, Nicola A Hanania
Nov 6, 2020·Inflammopharmacology·Madhur D ShastriPhilip M Hansbro
Oct 29, 2020·Signal Transduction and Targeted Therapy·Cuixue WangHai Tian
Oct 31, 2017·Journal of the American Medical Directors Association·Barbara J Messinger-RapportJulie K Gammack

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT00430729
NCT00313209
NCT00424268
NCT00242320
NCT00076089
NCT01443845
NCT01313494
NCT01329029
NCT01572948

Software Mentioned

Review Manager ( RevMan
Cochrane

Related Concepts

Related Feeds

CFTR Mutant Structural Therapy

Over 1700 different mutations in the CFTR genes have been shown to cause cystic fibrosis. Here is the latest research on structural therapy for CFTR mutants.